GPS167
GPS167 is a CLK kinase inhibitor that potently and selectively inhibits recombinant human CLK1, CLK2 and CLK4. By inhibiting CLK-mediated phosphorylation of SRSF10, GPS167 upregulates the protein-binding ability of CLK1 and CLK4 with SRSF10, downregulates oncogenic BCLAF1-L and upregulates tumor-suppressive BCLAF1-S, regulates alternative splicing of genes such as MDM2 and MDM4, stabilizes p53 protein and induces DNA damage, ultimately triggering tumor cell apoptosis. GPS167 can block the epithelial-mesenchymal transition process of tumors, activate intracellular double-stranded RNA-mediated antiviral immune responses, and produce synergistic cytotoxicity when combined with microtubule-targeting drugs. GPS167 can be used in research related to various cancers including colorectal cancer.
For research use only. We do not sell to patients.
- CAS No.: 3034312-19-8
- Formula: C17H13N5OS
- Molecular Weight:335.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[2]|
Caspase 3 |
PARP |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-22 | IC50 |
100 μM
Compound: 43; GPS167
|
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 36876904] |
In Vitro
GPS167 potently and selectively inhibits recombinant human CLK1, CLK2 and CLK4 with IC50 values of 0.0896 μM, 0.0820 μM and 0.1230 μM, and shows weak or negligible activity against most other tested human kinases. In non-radioactive proximity assays, GPS167 yields an IC50 of 0.5069 μM for CLK1 and displays poor inhibitory potency toward DYRK1A and DYRK1B; and its inhibitory effect on SRSF10 phosphorylation is preferential than its inhibitory effect on SRSF1 phosphorylation[1][2].
GPS167 (1-30 μM; 6 h) increases Thr212-Tau phosphorylation in SH-SY5Y cells expressing human 4R-Tau[1].
GPS167 (48 h) is non-cytotoxic to HT22 murine hippocampal neuronal cells, with an IC50 for viability >100 μM[1].
GPS167 (0.05-100 μM; 48 h) modulates BCLAF1 alternative splicing in HCT116 cells, reducing BCLAF1-L variant levels with an EC50 of ~2 μM[2].
GPS167 (10-20 μM; 24 h cell incubation, 10 min pull-down incubation) promotes dephosphorylation of specific serine residues on SRSF10 and increases the interaction between SRSF10 and CLK1 in HCT116 cells[2].
GPS167 (10 μM; 0-80 h) induces potent cytotoxicity in human colorectal cancer cell lines (HCT116, COLO205, SW620) but has minimal effects on Caco-2 cells and normal colonocyte cell lines (CRL-1831, CRL-1790)[2].
GPS167 induces apoptosis in human colorectal cancer HCT116, COLO205 and SW620 cells accompanied by elevated cleaved PARP and cleaved caspase-3, whereas no apoptotic effect is observed in Caco-2 and normal colon epithelial CRL-1831 cells. It inhibits cancer cell migration as evidenced by decreased scratch wound closure rate[2].
GPS167 (10-20 μM; up to 120 h viability, up to 84 h cytotoxicity, 72 h PARP cleavage) impairs viability, induces cytotoxicity and apoptosis, and disrupts structure in human and mouse colorectal cancer organoids, but has minimal effects on normal colorectal organoids[2].
GPS167 (10-20 μM; 24 h viability and caspase activity, up to 72 h cytotoxicity) elicits p53-dependent growth inhibition, cytotoxicity, and apoptosis in HCT116 colorectal cancer cells, with increased p53 expression and DNA damage observed in p53-proficient cells[2].
GPS167 (8 days) in NALM-6 cells, depletion of genes involved in mitotic cell cycle checkpoint/chromosome segregation increases sensitivity to GPS167, while depletion of mitotic spindle assembly-related genes reduces GPS167 sensitivity[3].
GPS167 disrupts the expression and alternative splicing of EMT-relevant genes, including FLNB and CD44, in HCT116 colorectal cancer cells[3].
GPS167 (1 μM; 4 days) in MCF10A breast epithelial cells, upregulates the epithelial marker ECAD (both with and without TGF-β treatment) and inhibits TGF-β-induced EMT morphological changes, without altering mesenchymal marker expression[3].
GPS167 (20 μM; up to 72 h) in HCT116 colorectal cancer cells, depletion of the dsRNA sensor DHX33 significantly reduces cytotoxicity over 72 hours[3].
GPS167 inhibits proliferation and induces p53-dependent apoptosis in multiple cancer cell lines (including colorectal, melanoma, leukemia, breast, ovarian, and renal) and colorectal organoids, while sparing normal colonocyte cells and organoids[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SH-SY5Y cells expressing human 4R-Tau
-
Concentration:1, 10, 30 μM
-
Incubation Time:6 h
-
Result:Does not reduce Thr212-Tau phosphorylation.
Induces an increase in Thr212-Tau phosphorylation relative to DMSO-treated control cells at tested concentrations.
-
Cell Line:Human colorectal cancer HCT116 cells
-
Concentration:0.05, 1, 2.5, 5, 10, 25, 50, 100 μM
-
Incubation Time:48 h
-
Result:Dose-dependently shifted BCLAF1 splicing from the pro-oncogenic BCLAF1-L variant to the shorter BCLAF1-S variant.
Induced statistically significant shifts at concentrations from 5 to 100 μM.
Achieved an EC50 of approximately 2 μM for the splicing shift.
-
Cell Line:Human colorectal cancer HCT116 cells (endogenous and Flag-tagged SRSF10)
-
Concentration:10, 20 μM (cell incubation); 20 μM (pull-down assay)
-
Incubation Time:24 h (cell incubation); 10 min (pull-down assay)
-
Result:Induced partial dephosphorylation of endogenous and Flag-tagged SRSF10, as shown by faster migrating bands on immunoblots.
Reduced phosphorylation of SRSF10 peptide SRSRSFDYNYR (serines 129, 131, 133) by 3-fold and decreased phosphorylation of serine 23 in peptide NVADDTRSEDLRT relative to control.
Increased the recovery of His-SRSF10 in GST-CLK1 pull-down assays by ~3-fold compared to control.
-
Cell Line:MCF10A breast epithelial cells
-
Concentration:1 μM (alone or with TGF-β); 4 ng/mL hTGFb-1
-
Incubation Time:4 days (GPS167 alone or with TGF-β); 24 h (TGF-β induction)
-
Result:In TGF-β-treated cells, stimulated expression of the epithelial marker ECAD compared to DMSO control.
In non-TGF-β-treated cells, promoted ECAD expression.
Expression of mesenchymal markers NCAD and vimentin was unchanged.
Prevented the elongated, spindle-shaped cell morphology characteristic of TGF-β-induced EMT.
Chemical Information
-
CAS No. 3034312-19-8
-
Molecular Weight 335.38
-
Formula C17H13N5OS
-
SMILES
O=C(C1=CSC(NC2=CC=CC=C2)=N1)NC3=CC4=C(NN=C4)C=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
[1]. Lindberg MF, et al. Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases. J Med Chem. 2023;66(6):4106-4130. [Content Brief]
[2]. Sohail M, et al. A novel class of inhibitors that target SRSF10 and promote p53-mediated cytotoxicity on human colorectal cancer cells. NAR Cancer. 2021;3(2):zcab019. Published 2021 May 25. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)